Capstone Investment Advisors LLC Takes $708,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Capstone Investment Advisors LLC purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 35,607 shares of the biopharmaceutical company’s stock, valued at approximately $708,000.

Several other large investors also recently added to or reduced their stakes in the stock. Pacer Advisors Inc. boosted its holdings in shares of Catalyst Pharmaceuticals by 130,918.8% in the 2nd quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock worth $45,968,000 after purchasing an additional 2,965,310 shares during the period. Vanguard Group Inc. raised its stake in shares of Catalyst Pharmaceuticals by 12.1% in the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock valued at $127,212,000 after acquiring an additional 860,244 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 15.2% in the 2nd quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock worth $33,702,000 after acquiring an additional 287,300 shares during the last quarter. Integral Health Asset Management LLC purchased a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth about $4,260,000. Finally, Dimensional Fund Advisors LP grew its holdings in Catalyst Pharmaceuticals by 9.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock valued at $46,479,000 after purchasing an additional 263,099 shares during the last quarter. 79.22% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

CPRX has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Stephens initiated coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price on the stock. Citigroup upped their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, Truist Financial lifted their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a report on Monday, November 11th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $31.14.

Catalyst Pharmaceuticals Price Performance

Shares of Catalyst Pharmaceuticals stock opened at $22.34 on Friday. The firm’s 50-day moving average is $21.23 and its two-hundred day moving average is $18.72. Catalyst Pharmaceuticals, Inc. has a 1 year low of $13.00 and a 1 year high of $24.27. The stock has a market cap of $2.66 billion, a price-to-earnings ratio of 18.93, a PEG ratio of 3.44 and a beta of 0.75.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.